| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $6.26B | +5.5% |
| Gross profit | $3.61B | — |
| Operating income | $1.13B | — |
| Net income | $0.87B | +56.8% |
| Gross margin | 57.6% | Net margin 13.9% |
| Revenue Q/Q | +5.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| Diagnostics | $2.21B | 35.3% |
| Biotechnology | $1.72B | 27.5% |
| Life Sciences | $1.27B | 20.2% |
| Revenuefrom Contractwith Customer Measurement Nonrecurring | $1.06B | 17.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.65B | 42.4% |
| R&D | $0.41B | 6.6% |
| SG&A | $2.07B | 33.1% |
| Tax & other | $0.26B | 4.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
DRI ・ DDOG ・ DVA ・ DECK ・ DE ・ DELL ・ DAL ・ DVN ・ DXCM ・ FANG ・ DLR ・ DG
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies